Literature DB >> 19328570

Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.

Steven F Petit1, Hugo J W L Aerts, Judith G M van Loon, Claudia Offermann, Ruud Houben, Bjorn Winkens, Michel C Ollers, Philippe Lambin, Dirk De Ruysscher, André L A J Dekker.   

Abstract

PURPOSE: To characterize the relationship between pre-radiotherapy (18)Fluorodeoxyglucose (FDG) uptake in a tumour voxel, radiation dose and the probability to achieve metabolic control in the tumour voxel after radiotherapy.
MATERIALS AND METHODS: Thirty-nine patients with inoperable stage I-III non-small cell lung cancer, treated with radiotherapy (RT) alone or sequential chemo radiation were analysed retrospectively. Twenty-two showed metabolic active areas in the tumour 3 months post-radiotherapy, which is known to be a surrogate for persistent local tumour failure and worse survival. Pre- and post-RT FDG-PET-CT scans were registered and the metabolic active zones within the tumour after RT were projected on the pre-RT scan. Multi-level logistic regression was performed to determine the relation between the FDG uptake if a voxel pre-RT and its metabolic state after RT.
RESULTS: The probability that a voxel is metabolically controlled (mVCP), decreased significantly with increasing FDG uptake in a voxel (SUV) (OR=0.72), increasing tumour volume (20 cm(3)) (OR=0.89) and increasing dose (Gy) (OR=0.99). Inter-patient differences in mVCP were substantial.
CONCLUSION: A methodology was presented to derive relationships between FDG uptake, dose and metabolic control. Although no strong dose effect relation was demonstrated, mVCP decreased with increasing FDG uptake and tumour volume.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328570     DOI: 10.1016/j.radonc.2009.02.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

1.  An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.

Authors:  Marie Wanet; Antoine Delor; François-Xavier Hanin; Benoît Ghaye; Aline Van Maanen; Vincent Remouchamps; Christian Clermont; Samuel Goossens; John Aldo Lee; Guillaume Janssens; Anne Bol; Xavier Geets
Journal:  Strahlenther Onkol       Date:  2017-07-21       Impact factor: 3.621

Review 2.  The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning.

Authors:  S Alobaidli; S McQuaid; C South; V Prakash; P Evans; A Nisbet
Journal:  Br J Radiol       Date:  2014-07-23       Impact factor: 3.039

3.  Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging.

Authors:  Stephen R Bowen; Daniel S Hippe; W Art Chaovalitwongse; Chunyan Duan; Phawis Thammasorn; Xiao Liu; Robert S Miyaoka; Hubert J Vesselle; Paul E Kinahan; Ramesh Rengan; Jing Zeng
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

4.  The biology underlying molecular imaging in oncology: from genome to anatome and back again.

Authors:  R J Gillies; A R Anderson; R A Gatenby; D L Morse
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

Review 5.  PET-CT for radiotherapy treatment planning and response monitoring in solid tumors.

Authors:  Johan Bussink; Johannes H A M Kaanders; Winette T A van der Graaf; Wim J G Oyen
Journal:  Nat Rev Clin Oncol       Date:  2011-01-25       Impact factor: 66.675

6.  Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.

Authors:  Stephen R Bowen; Richard J Chappell; Søren M Bentzen; Michael A Deveau; Lisa J Forrest; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-06-08       Impact factor: 6.280

7.  Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.

Authors:  Mathieu Hatt; Catherine Cheze-le Rest; Angela van Baardwijk; Philippe Lambin; Olivier Pradier; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-10-11       Impact factor: 10.057

8.  Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.

Authors:  P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost
Journal:  Radiother Oncol       Date:  2013-09-14       Impact factor: 6.280

9.  Application of FDG-PET/CT in Radiation Oncology.

Authors:  Jun Li; Ying Xiao
Journal:  Front Oncol       Date:  2013-04-11       Impact factor: 6.244

10.  Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user's perspective.

Authors:  Ingo G Steffen; Frank Hofheinz; Julian Mm Rogasch; Christian Furth; Holger Amthauer; Juri Ruf
Journal:  EJNMMI Res       Date:  2013-12-27       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.